cabotegravir-rilpivirine
Real-World Data Show Continued Virologic Suppression With Cabenuva
At CROI 2025, new research has shown high rates of continued virologic suppression with cabotegravir-rilpivirine ...
MARCH 25, 2025
Long-Acting Injectable ART as Effective as Daily Pills
CAB+RPV LA antiretroviral therapy was as effective as daily BIC/FTC/TAF in maintaining viral suppression among ...
FEBRUARY 23, 2023
FDA Grants New Indication for Cabenuva for Every-8–Week Dosing
The FDA extended the time between shots of Cabenuva to every two months to treat HIV-1 infection in virologically ...
FEBRUARY 1, 2022
Load more